(Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) To the Director of the United States I 1. Name of conveying party(ies): Cytran, Inc. Additional name(s) of conveying party(ies) attached? Assignment	Attorney's Docket No. 102466591 2. Name and address of receiving party(ies): Name: Melmotte, Inc. Internal Address: Street Address: 3900 Paramount Parkway					
To the Director of the United States 1. Name of conveying party(ies): Cytran, Inc. Additional name(s) of conveying party(ies) attached? Y 3. Nature of conveyance: Assignment	2. Name and address of receiving party(ies): Name: Melmotte, Inc. Internal Address: Street Address: 3900 Paramount Parkway	thereof.				
Cytran, Inc. Additional name(s) of conveying party(ies) attached? Y B. Nature of conveyance: Assignment Merger Security Agreement Change of Name	2. Name and address of receiving party(ies): Name: Melmotte, Inc. Internal Address: Street Address: 3900 Paramount Parkway					
Additional name(s) of conveying party(ies) attached?	Internal Address: Street Address: 3900 Paramount Parkway					
3. Nature of conveyance: X Assignment	Street Address: 3900 Paramount Parkway					
■ Assignment	3900 Paramount Parkway					
	City Marricvilla State: NC					
Execution Date: 3/19/03	City, Worthsville State, NC 2	Zip: 27560				
Execution Date: 3/19/03	Additional name(s) & address(es) attached?	es 🕱 No				
4. Application number(s) or patent number(s):						
If this document is being filed together with a new	application, the execution date of the application is:					
A. Patent Application No.(s) 10/146,447 10/164,693 09/872,503 09/535,429 09/506,430 09/882,779 10/076,707 Additional num	6,100,380 5,807,830 5,789,384 5,8	136,788 311,399 972,894				
Name and address of party to whom corresponder concerning document should be mailed:		ed: 25				
Name: Allen R. Baum	7 Total foo (27 CED 2.41)	1000.00				
Internal Address:	7. Total fee (37 CFR 3.41)\$					
Burns, Doane, Swecker & Mathis, L.L.P. P.O. Box 1404	\	☐ Enclosed Authorized to be charged to deposit account				
Street Address:	8. Deposit account number:					
	02-4800					
City: Alexandria State: VA Zip: 2		account.)				
ים	O NOT USE THIS SPACE					
. Statement and Signature.						
To the best of my knowledge and belief, the forego of the original document.	oing information is true and correct and any attached copy is a tr	ие сору				
Sherry M. Carty , Reg. No. 51,534	Sheyn M. Carty Juno 2	,2003				
Name of Person Signing	Signature Dat	te				
Total number of pages including cover	r sheet, attachments, and documents: 6					
Director of the United States Patent an	ecorded with required cover sheet information to: d Trademark Office / Mail Stop Assignment Recordation Services 1450 / Alexandria, VA 22313-1450					

Additional Patent Numbers for Recordation Form Cover Sheet

6,139,862

6,096,713

5,770,576

6,346,514

5,538,951

5,767,087

ASSIGNMENT

THIS ASSIGNMENT, by <u>CYTRAN, INC.</u>, a corporation duly organized under and pursuant to the laws of <u>WASHINGTON</u> and having its principal place of business at <u>10230 N.E. Points Drive</u>, <u>Suite 530, Kirkland, Washington 98033</u> (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title, and interest set forth in the U.S. Patents and Applications for Patent listed in Schedule A and the inventions disclosed therein.

WHEREAS, MELMOTTE, INC. a corporation duly organized under and pursuant to the laws of DELAWARE, and having its principal place of business at 3900 PARAMOUNT PARKWAY, MORRISVILLE, NORTH CAROLINA, 27560, U.S.A. (hereinafter referred to as "the Assignee"), is desirous of acquiring the entire right, title, and interest in and to said U.S. Patents, Patent Applications, and inventions, the right to file applications on said inventions and the entire right, title and interest in and to any applications, including provisional applications for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned U.S. Patents, Patent Applications, and inventions vested in Assignor, the right to file applications on said inventions and the entire right, title, and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said applications vested in Assignor, and any and all Letters Patent or Patents of the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, continuations, and continuations-in-part of said applications, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, to the extent the Assignor is the owner of any right, title, and interest in and to the inventions set forth in said patents and applications, including provisional applications, above-mentioned, are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

3/00)

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said inventions or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any applications claiming priority to said applications, divisions, continuations, or continuations-in-part of any applications for Letters Patent or Patents, or any reissues or extensions of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of Letters Patent or Patents for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby request the Commissioner of Patents to issue any and all said Letters Patent of the United States to the Assignee as the Assignee of said inventions, the Letters Patent to be issued for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date Murch 19th 2003 Signature of Assignor Feter Spans

Name: Peter Spurging

Title:

Vice President

Company: Cytran, Inc.

Schedule A

Title	Application	Filing Date	Patent	Attomey
	Number		Number	Docket No.
Analogs of L-Glu-L-Trp Having	10/146,447	05/14/2002		033559-002
Pharmacological Activity				
Analogs of L-Glu-L-Trp Having	09/535,429	03/23/2000		033599-005
Pharmacological Activity			_	
Analogs of L-Glu-L-Trp Having	09/055,051	04/03/1998	6,060,452	033599-093
Pharmalogical Activity			_	
Immunomodulating Peptides and	08/484,511	06/07/1995	6,100,380	033599-036
Methods of Use				
Immunomodulating Peptides and	08/144,779	10/28/1993	6,066,622	033599-038
Methods of Use			_	. L
Pharmaceutical Angiostatic Dipeptide	08/614,764	03/13/1996	5,902,790	033599-013
Compositions and Methods of Use	[[
Thereof	<u> </u>		_	
Method for Treatment of Purulent	08/452,061	05/26/1995	5,807,830	033599-073
Inflammatory Diseases			<u> </u>	
Methods for Normalizing Numbers of	08/452,411	05/26/1995	5,728,680	033599-072
Lymphocytes				
Methods of Identifying Cytomedines,	09/882,779	06/14/2001		033599-039
Compositions and Uses Thereof				
Methods of Treating Complications in	08/977,279	11/24/1997	6,368,788	033599-014
Immunodepressed States Resulting	1			
From HIV Infection	}	1	}	}
Pharmaceutical Dipeptide	09/057,347	04/08/1998	6,139,862	033599-040
Compositions and Methods of Use		1		
Thereof	Ì	Ì		
Pharmaceutical Tryptophan	10/164,693	06/06/2002		033599-042
Containing Dipeptide Compositions		1	1	
and Methods of Use Thereof			Ì	
Pharmaceutical Dipeptide	08/415,099	03/31/1995	5,789,384	033599-043
Compositions and Methods of Use			1	ľ
Thereof				
Pharmaceutical for the Therapy of	08/482,121	06/07/1995	5,814,611	033599-069
Immune Deficiency Conditions				
Pharmaceutical Preparation for the	09/144,960	09/01/1998	6,136,788	033599-070
Therapy of Immune Deficiency				
Conditions				
Pharmaceutical Dipeptide	08/450,904	05/26/1995	5,811,399	033599-071
Compositions and Methods of Use		1		
Thereof: Immunodepressants	((į	[
Peptides having Potassium Channel	08/908,328	08/07/1997	5,972,894	033599-102
Opener Activity				
Pharmaceutical Angiostatic Dipeptide	09/260,190	03/01/1999	6,096,713	033599-089
Compositions and Methods of Use	-			
Thereof			1	
Pharmaceutical Angiostatic Dipeptide	09/506,430	02/17/2000		033599-015
Compositions and Methods of Use				
Thereof				
Pharmaceutical Dipeptide	10/076,707	02/14/2002		033599-003
Compositions and Methods of Use				
Thereof: Immunostimulants		<u></u>	<u> </u>	
Pharmaceutical Dipeptide	08/452,077	05/26/1995	5,770,576	033599-104
Compositions and Methods of Use				
Thereof: Systemic Toxicity				1

1

Schedule A (continued)

Pharmaceutical Lysine-Containing	09/368,449	08/04/1999	6,346,514	033599-012
Polypeptide Compositions and				
Methods of Use Thereof				
Pharmaceutical Lysine-Containing	09/872,503	05/31/2001		033599-019
Polypeptide Compositions and				1
Methods of Use Thereof				
Pharmaceutical Preparation for the	08/337,341	11/10/1994	5,538,951	033599-011
Therapy of Immune Deficiency				
Conditions				
Pharmaceutical Preparation for the	08/486,044	06/07/1995	5,767,087	033599-103
Therapy of Immune Deficiency				
Conditions			1	

2